Cooper Companies, Inc.
Most Recent
Cooper Companies Reported Mixed 2Q15 Results
Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.
Analysts’ Recommendations for Haemonetics and Peers in March 2018
In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.
Inside Johnson & Johnson’s Vision Care Performance in 3Q17
In 3Q17, JNJ vision care generated revenues of $1.1 billion, which reflected a ~48% YoY (year-over-year) rise and a 3% QoQ (quarter-over-quarter) rise.
Novartis Expects to Restore Alcon’s Profitability in the Future
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
Will Novartis’s Alcon Business See Growth in 2017?
Novartis (NVS) expects its Alcon business to report low-single-digit revenue growth in 2017.
Stellar YTD 2016 for MFS Massachusetts Investors Growth Stock Fund
The MFS Massachusetts Investors Growth Stock Fund – Class A (MIGFX) is the only fund in this review that has outperformed the passively managed SPDR S&P 500 ETF Trust (SPY).
Lone Pine Adds New Stake in The Cooper Companies
Cooper’s results for fiscal 1Q15 beat the EPS estimates, but it missed on revenue. Cooper’s revenue grew 10% year-over-year to $445.2 million.
